p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer

Early detection of cancer in the general population: a blinded case–control study of p53 autoantibodies in colorectal cancer

(2012) J W Pedersen et al.   BRITISH JOURNAL OF CANCER

Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera

(2012) H. Lu et al.   Cancer Prevention Research

Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

(2011) D. W. Cramer et al.   Cancer Prevention Research

Comparison of candidate serologic markers for type I and type II ovarian cancer

(2011) Dan Lu et al.   GYNECOLOGIC ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum autoantibodies as biomarkers for early cancer detection

(2009) Hwee Tong Tan et al.   FEBS Journal

The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer

(2009) Dirk O. Bauerschlag et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY